完成两剂灭活疫苗的成人中低剂量与标准剂量AZD1222加强针的随机临床试验
该双盲随机对照试验纳入422名已完成两剂CoronaVac灭活疫苗的18-59岁成人,比较标准剂量(5×10^10病毒颗粒)与低剂量(2.5×10^10病毒颗粒)AZD1222加强针的免疫原性和反应原性。结果显示低剂量组对delta变异株的sVNT抑制率与标准剂量组相当(第14天GMR 1.00,95%CI 0.98-1.02),抗S-RBD IgG略低(GMR 0.84,95%CI 0.76-0.93),但发热和肌痛发生率显著更低。作者认为在资源有限地区可考虑半剂量AZD1222加强。
要点
- 低剂量组第14天对delta变异株sVNT的GMR为1.00(95%CI 0.98-1.02),与标准剂量组相当。
- 低剂量组抗S-RBD IgG的GMR为0.84(95%CI 0.76-0.93),低于标准剂量组。
- 低剂量组发热6.8% vs 标准剂量组25.0%,肌痛51.9% vs 70.7%,均显著更低。
核心结论
- 完成两剂灭活SARS-CoV-2疫苗后,半剂量AZD1222加强针具有非劣效免疫原性,且全身反应原性更低;作者认为在资源有限地区应考虑分次低剂量AZD1222加强。
研究设计与样本
- 双盲、随机、对照试验,纳入18-59岁、完成2剂CoronaVac(间隔21-28天)超过2个月的健康成人422名,随机接受标准剂量(5×10^10病毒颗粒)或低剂量(2.5×10^10病毒颗粒)AZD1222肌内注射。
主要发现
- 2021年7-8月入组422名成人,中位年龄44岁(IQR 36-51),距CoronaVac中位间隔77天(IQR 64-95)。
- 基线时针对delta变异株sVNT几何均值(GM)为18.1%抑制(95%CI 16.4-20.0),抗S-RBD IgG为111.5 BAU/ml(95%CI 105.1-118.3)。
- 标准剂量组第14天delta sVNT GM为95.6%抑制(95%CI 94.3-97.0),抗S-RBD IgG为1975.1 BAU/ml(95%CI 1841.7-2118.2);第90天分别为89.4%抑制(95%CI 86.4-92.4)和938.6 BAU/ml(95%CI 859.9-1024.4)。
- 低剂量组相比标准剂量组,第14天delta sVNT的GMR为1.00(95%CI 0.98-1.02),抗S-RBD IgG的GMR为0.84(95%CI 0.76-0.93);第90天分别为0.98(95%CI 0.94-1.03)和0.89(95%CI 0.79-1.00)。
- 低剂量组发热发生率6.8% vs 标准剂量组25.0%,肌痛发生率51.9% vs 70.7%,低剂量组均显著更低。
临床怎么用
- 作者认为在资源有限地区应考虑使用分次低剂量AZD1222加强针。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunogenicity of inactivated SARS-CoV-2 vaccine has waning antibody over time. With the emergence of the SARS-CoV-2 delta variant, which requires higher neutralizing antibody to prevent infection, a booster dose is needed. OBJECTIVE: To evaluate immunogenicity and reactogenicity of standard- versus low-dose ChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults. METHODS: A double-blinded, randomized, controlled trial of adult, aged 18-59 years, with completion of 2-dose CoronaVac at 21-28 days apart for more than 2 months was conducted. Participants were randomized to receive AZD1222 (Oxford/AstraZeneca) intramuscularly; standard dose (SD, 5x1010 viral particles) or low dose (LD, 2.5x1010 viral particles). Surrogate virus neutralization test (sVNT) against wild type and delta variant, and anti-spike-receptor-binding-domain IgG (anti-S-RBD IgG) were compared as geometric mean ratio (GMR) at day 14 and 90 between LD and SD arms. RESULTS: From July-August 2021, 422 adults with median age of 44 (IQR 36-51) years were enrolled. The median interval from CoronaVac to AZD1222 booster was 77 (IQR 64-95) days. At baseline, geometric means (GMs) of sVNT against delta variant and anti-S-RBD IgG were 18.1%inhibition (95% CI 16.4-20.0) and 111.5 (105.1-118.3) BAU/ml. GMs of sVNT against delta variant and anti-S-RBD IgG in SD were 95.6%inhibition (95% CI 94.3-97.0) and 1975.1 (1841.7-2118.2) BAU/ml at day 14, and 89.4%inhibition (86.4-92.4) and 938.6 (859.9-1024.4) BAU/ml at day 90, respectively. GMRs of sVNT against delta variant and anti-S-RBD IgG in LD compared to SD were 1.00 (95% CI 0.98-1.02) and 0.84 (0.76-0.93) at day 14, and 0.98 (0.94-1.03) and 0.89 (0.79-1.00) at day 90, respectively. LD recipients had significantly lower rate of fever (6.8% vs 25.0%) and myalgia (51.9% vs 70.7%) compared to SD. CONCLUSION: Half-dose AZD1222 booster after 2-dose inactivated SARS-CoV-2 vaccination had non-inferior immunogenicity, yet lower systemic reactogenicity. Fractional low-dose AZD1222 booster should be considered especially in resource-constrained settings.
引用
- Nanthapisal S, Puthanakit T, Jaru-Ampornpan P, et al. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. Vaccine. 2022. PMID: 35341647. doi:10.1016/j.vaccine.2022.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。